Revolution Medicines (RVMD) Preferred Stock Liabilities (2019)
Revolution Medicines (RVMD) posted quarterly Preferred Stock Liabilities of $305.1 million for Q4 2019, little changed quarter-over-quarter from $305.1 million in Q3 2019.
Powered by 
Analysis
Revolution Medicines (RVMD) Preferred Stock Liabilities (2019) Analysis & Trends
Revolution Medicines' Preferred Stock Liabilities history runs 1 years deep, the most recent figure standing at $305.1 million for Q4 2019.
- In Q4 2019, Preferred Stock Liabilities changed N/A year-over-year to $305.1 million; the TTM figure through Dec 2019 stood at $305.1 million (changed N/A YoY), while the FY2019 annual figure was $305.1 million, up 48.77% from the prior year.
- Preferred Stock Liabilities for Q4 2019 stood at $305.1 million, roughly flat from $305.1 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $305.1 million in Q3 2019, with the low at $205.1 million in Q1 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Incyte | 25.44 Bn | 20.91 Bn | 1.57 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2019 | 305.11 Mn |
| Sep 30, 2019 | 305.11 Mn |
| Jun 30, 2019 | 295.02 Mn |
| Mar 31, 2019 | 205.08 Mn |